Reformulation Firms Aim To Deliver Better Biotech IPOs In 2011
Can biotech breakthrough the IPO malaise in 2011 with new formulations?
You may also be interested in...
Nothing has arguably hurt pharmaceutical investors and dealmakers quite so often and with such force as novel pain drug development failures. As a result, a once hot field has gone cold. Despite setbacks, great strides have been made in understanding the complex biology of pain. Scientists have discovered numerous new pain pathway targets with the potential for designing effective agents with fewer off-target effects. Improvements that make preclinical studies more predictive of clinical success are also opening up new opportunities. At the same time, drug developers now understand better how to design drug trials that can segment patient populations to demonstrate therapeutic efficacy more precisely, potentially reducing placebo effects and paving the way for an era of personalized pain medicine.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.